Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$6.21 - $11.05 $2,279 - $4,055
-367 Reduced 40.11%
548 $6,000
Q3 2023

Nov 14, 2023

SELL
$10.26 - $15.7 $163,954 - $250,886
-15,980 Reduced 94.58%
915 $9,000
Q2 2023

Aug 15, 2023

BUY
$7.28 - $14.32 $122,995 - $241,936
16,895 New
16,895 $242,000

Others Institutions Holding PHAT

About Phathom Pharmaceuticals, Inc.


  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $172M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Vestcor Inc Portfolio

Follow Vestcor Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vestcor Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vestcor Inc with notifications on news.